Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 10.17B 9.13B 8.43B 7.65B 14.29B 966B 14.46B 101B 40.14B 507B 38.19B 37.37B 1,606B P/E 2026 *
-70.4x
P/E 2027 * 84.6x
Enterprise Value 9.65B 8.66B 7.99B 7.25B 13.55B 916B 13.72B 95.84B 38.06B 480B 36.21B 35.44B 1,523B EV / Sales 2026 *
6.31x
EV / Sales 2027 * 4.36x
Free-Float
94.17%
Yield 2026 *
-
Yield 2027 * -
1 day-1.54%
1 week-5.20%
Current month-13.86%
1 month-16.04%
3 months-19.43%
6 months-15.98%
Current year-25.45%
1 week 428.32
Extreme 428.315
462.5
1 month 428.32
Extreme 428.315
518.66
Current year 416.21
Extreme 416.21
598.79
1 year 393.6
Extreme 393.605
615
3 years 120.65
Extreme 120.65
615
5 years 52.33
Extreme 52.33
615
10 years 13.09
Extreme 13.0886
615
Manager TitleAgeSince
Chief Executive Officer 59 2023-09-07
Director of Finance/CFO 62 2024-03-10
Chief Tech/Sci/R&D Officer 58 2025-04-20
Director TitleAgeSince
Director/Board Member 74 2016-06-30
Director/Board Member 68 2016-08-10
Director/Board Member 64 2019-06-26
Date Insider Type Main position Quantity % Market Cap. Importance
9/11/26 Sell

Chief Executive Officer

-5,221 0.0226%
8/17/26 Sell

General Counsel

-664 0.0029%
8/15/26 Free

Director

1,725 0.0075%
Change 5-day change 1-year change 3-year change Capi.($)
-1.55%-5.20%+1.15%+244.14% 10.17B
+0.65%-3.56%+33.53%+60.50% 63.48B
+2.30%+1.86%+12.46%+83.17% 54.55B
-1.13%+0.83%+10.28%+101.86% 53.59B
+2.65%+0.37%+27.28%+56.72% 44.75B
+2.29%-2.88%+18.46%+101.13% 41.62B
+0.73%-2.98%+224.03%+927.19% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+46.37%+105.35%+92.62% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +3.95%-0.96%+46.85%+170.99% 39.06B
Weighted average by Cap. +3.13%-0.43%+46.24%+163.74%

Financials

2026 *2027 *
Net sales 1.53B 1.37B 1.27B 1.15B 2.15B 145B 2.17B 15.18B 6.03B 76.07B 5.74B 5.61B 241B 2.12B 1.9B 1.76B 1.59B 2.98B 201B 3.02B 21.08B 8.37B 106B 7.96B 7.79B 335B
Net income -182M -163M -151M -137M -256M -17.29B -259M -1.81B -718M -9.06B -683M -669M -28.73B 171M 154M 142M 129M 241M 16.27B 244M 1.7B 676M 8.53B 643M 629M 27.04B
Net Debt -527M -473M -437M -396M -740M -50.05B -749M -5.24B -2.08B -26.23B -1.98B -1.94B -83.19B -924M -829M -766M -694M -1.3B -87.77B -1.31B -9.18B -3.65B -46B -3.47B -3.39B -146B
Projected Income Statement - Annual - Madrigal Pharmaceuticals, Inc.
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
26-10-28 $434.20 -1.39% 92,213
26-10-27 $440.33 +0.59% 209,579
26-10-26 $437.74 +0.81% 275,872
26-10-23 $434.24 -4.21% 234,852
26-10-22 $453.34 -1.01% 212,688
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Madrigal Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
440.33USD
Average target price
685.22USD
Spread / Average Target
+55.62%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Madrigal Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. MDGL Stock